journal article·2025-10-01Open access

Metabolic adaptation and fragility in healthy 3D in vitro skeletal muscle tissues exposed to chronic fatigue syndrome and Long COVID-19 sera

Sheeza Mughal, Félix Andújar-Sánchez, Maria Sabater-Arcis, Glória Garrabou, Joaquim Fernández-Solà, Jose Alegre-Martin, Ramon Sanmartin-Sentañes, Jesús Castro-Marrero, Anna Esteve-Codina, Eloi Casals, Juan M Fernández-Costa, Javier Ramón-Azcón

Biofabrication· Volume 17· Issue 4

Abstract

Abstract Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long Covid-19 (LC-19) are complex conditions with no diagnostic markers or consensus on disease progression. Despite extensive research, no in vitro model exists to study skeletal muscle wasting, peripheral weakness, or potential therapies. We developed 3D in vitro skeletal muscle tissues to map muscle adaptations to patient sera over time. Short exposures (48 H) to patient sera led to a significant reduction in muscle contractile strength. Transcriptomic analysis revealed the upregulation of protein translation, glycolytic enzymes, disturbances in calcium homeostasis, hypertrophy, and mitochondrial hyperfusion. Structural analyses confirmed myotube hypertrophy and elevated mitochondrial oxygen consumption In ME/CFS. While muscles initially adapted by increasing glycolysis, prolonged exposure (96–144 H) caused muscle fragility and weakness, with mitochondria fragmenting into a toroidal conformation. We propose that skeletal muscle tissue in ME/CFS and LC-19 progresses through a hypermetabolic state, leading to severe muscular and mitochondrial deterioration. This is the first study to suggest such transient metabolic adaptation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Fibromyalgia and Chronic Fatigue Syndrome Research · Exercise and Physiological Responses · Long-Term Effects of COVID-19

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (70)

Show source-provided references
1. Myalgic encephalomyelitis/chronic fatigue syndrome10.1300/J092v11n01_02 ↗
2. Cellular immune function in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)10.3389/fimmu.2019.00796 ↗
3. Post-exertional malaise in daily life and experimental exercise models in patients with myalgic encephalomyelitis/chronic fatigue syndrome10.3389/fphys.2023.1257557 ↗
4. Muscle abnormalities worsen after post-exertional malaise in long COVID10.1038/s41467-023-44432-3 ↗
5. Estimating prevalence, demographics, and costs of ME/CFS using large scale medical claims data and machine learning10.3389/fped.2018.00412 ↗
6. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)10.1186/s12967-018-1644-y ↗
7. Baker · 2021
8. Oxidative stress is a shared characteristic of ME/CFS and Long COVID10.4049/jimmunol.212.supp.0664.6496 ↗
9. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature10.3389/fmed.2023.1187163 ↗
10. Energy conservation/envelope theory interventions10.1080/21641846.2012.733602 ↗
11. Muscle energetics during explosive activities and potential effects of nutrition and training10.1007/s40279-014-0256-9 ↗
12. Characterization of post–exertional Malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome10.3389/fneur.2020.01025 ↗
13. Distinguishing features of long COVID identified through immune profiling10.1038/s41586-023-06651-y ↗
14. The effect of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) severity on cellular bioenergetic function10.1371/journal.pone.0231136 ↗
15. Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome10.1016/j.mito.2011.05.005 ↗
16. An isolated complex V inefficiency and dysregulated mitochondrial function in immortalized lymphocytes from ME/CFS patients10.3390/ijms21031074 ↗
17. Nath, deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome10.1038/s41467-024-45107-3 ↗
18. European network on myalgic encephalomyelitis/chronic fatigue syndrome (euromene): expert consensus on the diagnosis, service provision, and care of people with ME/CFS in Europe10.3390/medicina57050510 ↗
19. Organs-on-chips: trends and challenges in advanced systems integration10.1002/admi.202201618 ↗
20. Personalised organs-on-chips: functional testing for precision medicine10.1039/C8LC00827B ↗
21. Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome10.1371/journal.pone.0122982 ↗
22. Pathophysiology of skeletal muscle disturbances in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)10.1186/s12967-021-02833-2 ↗
23. Training‐on‐a‐chip: a multi‐organ device to study the effect of muscle exercise on insulin secretion in vitro10.1002/admt.202200873 ↗
24. Physical activity and exercise: strategies to manage frailty10.1016/j.redox.2020.101513 ↗
25. AIFM1 beyond cell death: an overview of this OXPHOS-inducing factor in mitochondrial diseases10.1016/j.ebiom.2022.104231 ↗
26. HTRA2/OMI-mediated mitochondrial quality control alters macrophage polarization affecting systemic chronic inflammation10.3390/ijms25031577 ↗
27. Histone methyltransferase SMYD1 regulates mitochondrial energetics in the heart10.1073/pnas.1800680115 ↗
28. SMYD1a protects the heart from ischemic injury by regulating OPA1-mediated cristae remodeling and supercomplex formation10.1007/s00395-023-00991-6 ↗
29. The sarcoplasmic reticulum of skeletal muscle cells: a labyrinth of membrane contact sites10.3390/biom12040488 ↗
30. Oxidative stress, mitochondrial damage and neurodegenerative diseases10.3969/j.issn.1673-5374.2013.21.009 ↗
31. Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease10.3389/fnins.2023.1244022 ↗
32. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy10.1083/jcb.200804077 ↗
33. Inhibiting fatty acid oxidation promotes cardiomyocyte proliferation10.1038/s41569-020-0361-4 ↗
34. PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy10.1038/s42255-023-00912-w ↗
35. Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation10.1016/j.mito.2019.07.009 ↗
36. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome10.1172/jci.insight.89376 ↗
37. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass10.1083/jcb.201211134 ↗
38. Estrogen receptor β controls muscle growth and regeneration in young female mice10.1016/j.stemcr.2020.07.017 ↗
39. In sex and gender factors affecting metabolic homeostasis, diabetes and obesity
40. Estrogen and glycemic homeostasis: the fundamental role of nuclear estrogen receptors ESR1/ESR2 in glucose transporter GLUT4 regulation10.3390/cells10010099 ↗
41. An engineered anisotropic skeletal muscle organoid‐on‐a‐chip for deciphering muscle response under intermittent hypoxia10.1002/adfm.202401564 ↗
42. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation10.7554/eLife.41351 ↗
43. Simultaneous impairment of mitochondrial fission and fusion reduces mitophagy and shortens replicative lifespan10.1038/srep07885 ↗
44. SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation10.1038/s41392-024-01836-x ↗
45. The bioenergetic health index: a new concept in mitochondrial translational research10.1042/CS20140101 ↗
46. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements10.1074/jbc.M116.774471 ↗
47. Altered fusion dynamics underlie unique morphological changes in mitochondria during hypoxia–reoxygenation stress10.1038/cdd.2011.13 ↗
48. 2015
49. Structural and functional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection10.1152/japplphysiol.00158.2023 ↗
50. Mitochondrial dysfunction as an underlying cause of skeletal muscle disorders10.3390/ijms232112926 ↗
51. Cooper · 2000
52. Signaling in muscle contraction10.1101/cshperspect.a006023 ↗
53. Purine and purinergic receptors in health and disease10.1002/mco2.359 ↗
54. Myalgic encephalomyelitis/chronic fatigue syndrome from current evidence to new diagnostic perspectives through skeletal muscle and metabolic disturbances10.1111/apha.14122 ↗
55. Superoxide dismutases: role in redox signaling, vascular function, and diseases10.1089/ars.2011.3999 ↗
56. The applications and mechanisms of superoxide dismutase in medicine, food, and cosmetics10.3390/antiox12091675 ↗
57. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging10.1007/s00204-023-03562-9 ↗
58. Compensatory upregulation of respiratory chain complexes III and IV in isolated deficiency of ATP synthase due to TMEM70 mutation10.1016/j.bbabio.2012.03.004 ↗
59. Myalgic encephalomyelitis: international consensus criteria10.1111/j.1365-2796.2011.02428.x ↗
60. Skin temperature circadian rhythms and dysautonomia in myalgic encephalomyelitis/chronic fatigue syndrome: the role of endothelin-1 in the vascular tone dysregulation10.3390/ijms24054835 ↗
61. Training-on-a-Chip: a multi-organ device to study the effect of muscle exercise on insulin secretion in vitro10.1002/admt.202200873 ↗
62. Taurine activates the AKT–mTOR axis to restore muscle mass and contractile strength in human 3D in vitro models of steroid myopathy10.1242/dmm.050540 ↗
63. Derivation and characterization of immortalized human muscle satellite cell clones from muscular dystrophy patients and healthy individuals10.3390/cells9081780 ↗
64. Muscle contraction velocity: a suitable approach to analyze the functional adaptations in elite soccer players
65. STAR: ultrafast universal RNA-Seq aligner10.1093/bioinformatics/bts635 ↗
66. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome10.1186/1471-2105-12-323 ↗
67. Limma powers differential expression analyses for RNA-sequencing and microarray studies10.1093/nar/gkv007 ↗
68. voom: precision weights unlock linear model analysis tools for RNA-seq read counts10.1186/gb-2014-15-2-r29 ↗
69. g: profiler—interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update)10.1093/nar/gkad347 ↗
70. Fast gene set enrichment analysis10.1101/060012 ↗